National Cancer Institute

Funding Opportunities

SPONSOR UPCOMING DEADLINE TITLE NEXT DEADLINE NEXT DEADLINE 2 FOA
National Cancer Institute (NCI) 9/22/2022 Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) –– –– RFA-CA-22-002
National Cancer Institute (NCI) 9/22/2022 Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) –– –– RFA-CA-22-001
National Cancer Institute (NCI) 9/25/2022 Cancer Research Education Grants Program – Courses for Skills Development (R25 Clinical Trial Not Allowed) –– –– PAR-21-278
National Cancer Institute (NCI) 9/25/2022 Cancer Research Education Grants Program – Research Experiences (R25 Clinical Trial Not Allowed) –– –– PAR-21-279
National Cancer Institute (NCI) 9/28/2022 Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical Trial Required) 6/30/2023 –– RFA-CA-22-029
National Cancer Institute (NCI) 9/28/2022 Cancer Adoptive Cellular Therapy Network (Can-ACT) for Adult Cancers (UG3/UH3 Clinical Trial Required) 6/30/2023 –– ––
National Cancer Institute (NCI) 9/28/2022 Cancer Adoptive Cellular Therapy Network (Can-ACT) Coordinating Center (U24 Clinical Trial Not Allowed) –– –– ––
National Cancer Institute (NCI) 9/30/2022 Research to Understand and Address the Survivorship Needs of Individuals Living with Advanced Cancer (R01 Clinical Trial Optional) –– –– RFA-CA-22-027
National Cancer Institute (NCI) 10/5/2022 Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional) 2/5/2023 –– PAR-22-099
National Cancer Institute (NCI) 10/5/2022 Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed) 2/5/2023 –– PAR-22-083

Can’t find what you’re looking for? Please contact Researchadmin@cancer.ufl.edu for assistance in finding additional funding opportunities.